Head to Head Review: ImmuCell (ICCC) versus Its Rivals

ImmuCell (NASDAQ:ICCC) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare ImmuCell to similar businesses based on the strength of its earnings, risk, analyst recommendations, institutional ownership, valuation, profitability and dividends.

Risk and Volatility

ImmuCell has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, ImmuCell’s competitors have a beta of -3.79, suggesting that their average stock price is 479% less volatile than the S&P 500.

Earnings and Valuation

This table compares ImmuCell and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ImmuCell	$27.64 million	-$1.04 million	128.25
ImmuCell Competitors	$3.53 billion	$3.17 billion	552.64

ImmuCell’s competitors have higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ImmuCell and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
ImmuCell Competitors	-2,380.61%	-219.90%	-15.56%

Analyst Recommendations

This is a breakdown of current ratings and target prices for ImmuCell and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0	1	0	0	2.00
ImmuCell Competitors	7806	13897	25803	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.32%. Given ImmuCell’s competitors stronger consensus rating and higher probable upside, analysts clearly believe ImmuCell has less favorable growth aspects than its competitors.

Summary

ImmuCell competitors beat ImmuCell on 9 of the 13 factors compared.

ImmuCell Company Profile

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.